Dermatoscopic features of thin (≤2 mm Breslow thickness) vs. thick (>2 mm Breslow thickness) nodular melanoma and predictors of nodular melanoma versus nodular non‐melanoma tumours: a multicentric collaborative study by the International Dermoscopy Society
Dimitrios Sgouros(National and Kapodistrian University of Athens), Alexander Stratigos(National and Kapodistrian University of Athens), Konstantinos Liopyris, Caterina Longo(Istituto Giannina Gaslini), D. Ioannides(Hospital Venereal and Skin Diseases Thessaloniki), Alexander Katoulis(National and Kapodistrian University of Athens), Αthanassios Kyrgidis, Christianna Oikonomou(National and Kapodistrian University of Athens), Alan C. Geller(Skin Cancer Foundation), Ralph P. Braun, Ángeles Flórez(Universidade de Santiago de Compostela), Josep Malvehy(Universitat de Barcelona), Gianluca Nazzaro(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Aimilios Lallas(Aristotle University of Thessaloniki), Isabelle Tromme(Cliniques Universitaires Saint-Luc), Scott W. Menzies(Royal Prince Alfred Hospital), Alexios Zarras(National and Kapodistrian University of Athens), Alon Scope(Memorial Sloan Kettering Cancer Center), Sven Lanssens, Dai Ogata(Unknown), Giuseppe Argenziano(Regione Campania), Chryssoula Papageorgiou(Aristotle University of Thessaloniki), Susana Puig(Instituto de Salud Carlos III), Maria Antonietta Pizzichetta(University of Trieste), L. Thomas(University of Liverpool), Zoé Apalla(Aristotle University of Thessaloniki), Iris Zalaudek(Azienda Sanitaria Universitaria Integrata di Trieste), Ashfaq A. Marghoob(Memorial Sloan Kettering Cancer Center), Grażyna Kamińska Winciorek(The Maria Sklodowska-Curie National Research Institute of Oncology), Harald Kittler(Medical University of Vienna), Horacio Cabo, Clio Desinioti(National and Kapodistrian University of Athens)
Cited by 25
Related Papers
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
|The Lancet Oncology|2016|1k
Skin Lesion Analysis Toward Melanoma Detection 2018: A Challenge Hosted by the International Skin Imaging Collaboration (ISIC)
|arXiv (Cornell University)|2019|990
Diagnosis and treatment of basal cell carcinoma: European consensus–based interdisciplinary guidelines
|European Journal of Cancer|2019|589
Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline
|European Journal of Cancer|2015|505